AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• AN2 Therapeutics Inc ANTX.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of two analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -36 cents to -31 cents per share.

• Reported revenue was zero​; analysts expected zero.

• AN2 Therapeutics Inc's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of $6.46 million.

• AN2 Therapeutics Inc shares had fallen by 0.9% this quarter and lost 23.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 19.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for AN2 Therapeutics Inc is $1.50, about 30% above its last closing price of $1.05

This summary was machine generated from LSEG data August 12 at 08:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)